Department of Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Cancer Center, Tulane Medical School, New Orleans, LA, USA.
Eur Urol. 2020 Oct;78(4):486-488. doi: 10.1016/j.eururo.2020.06.020. Epub 2020 Jul 5.
Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.
最近的数据显示，四种 PARP 抑制剂具有抗肿瘤活性，其中两种（奥拉帕利和芦卡帕利）已被美国食品和药物管理局批准用于治疗伴有特定 DNA 修复缺陷的转移性去势抵抗性前列腺癌。另外，talazoparib、veliparib 和 niraparib 的临床试验也正在进行中。在不久的将来，预计会有更多的进展。
